Perioperative management of anticoagulant and antiplatelet therapy

Heart

Volumn 104, Issue 17, 2018, Pages 1461-1467

  Tafur, Alfonso ^a,b   Douketis, James ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

atrial fibrillation; cardiac procedures and therapy; stroke; thromboembolic pulmonary vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CANGRELOR; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; PRASUGREL; RIVAROXABAN; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHADS2 SCORE; CLINICAL PRACTICE; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; ELECTIVE SURGERY; EVIDENCE BASED PRACTICE; HEART SURGERY; HEART TAMPONADE; HUMAN; MINOR SURGERY; PATIENT ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THROMBIN TIME; THROMBOEMBOLISM; TREATMENT INTERRUPTION; CHEMICALLY INDUCED; CLASSIFICATION; EDUCATION; MEDICATION THERAPY MANAGEMENT; OPERATIVE BLOOD LOSS; POSTOPERATIVE HEMORRHAGE; PROCEDURES; RISK ASSESSMENT; SURGERY;

ANTICOAGULANTS; BLOOD LOSS, SURGICAL; HUMANS; MEDICATION THERAPY MANAGEMENT; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RISK ADJUSTMENT; SURGICAL PROCEDURES, OPERATIVE;

EID: 85049141510     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-310581     Document Type: Article

References (50)

1. Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615-21.
2. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014;129:1850-9.
3. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015;113:625-32.
4. Tafur A, Wysokinski WE, McBane RD. Periprocedural anticoagulant management. Hosp Pract 2012;40:40-9.
5. Baron TH, Kamath PS, McBane RD. Antithrombotic therapy and invasive procedures. N Engl J Med 2013;369:1079-80.
6. Spyropoulos AC, Al-Badri A, Sherwood MW, et al. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016;14:875-85.
7. Douketis JD, Spyropoulos AC, Kaatz S, et al.Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-33.
8. Spyropoulos AC, Al-Badri A, Sherwood MW, et al. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 2016;14:2556-9.
9. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15.
10. Birnie DH, Healey JS, Essebag V. Device surgery without interruption of anticoagulation. N Engl J Med 2013;369:1571-2.
11. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:2638-44.
12. Tafur A, Douketis JD. Perioperative anticoagulant management in patients with atrial fibrillation : practical implications of recent clinical trials. Pol Arch Med Wewn 2015;125:666-71.
13. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:S299-339.
14. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBITAF). Circulation 2015;131:488-94.
15. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-96.
16. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-8.
17. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Heart Rhythm 2015;12:1162-8.
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
19. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
20. Douketis JD, Woods K, Foster GA, et al. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005;94:528-31.
21. Schulman S, Hwang HG, Eikelboom JW, et al. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. J Thromb Haemost 2014;12:1254-9.
22. Tafur AJ, McBane R, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012;10:261-7.
23. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26.
24. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004;110:1658-63.
25. Tafur AJ, Wysokinski WE, McBane RD, et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol 2012;23:1998-2005.
26. Omran H, Bauersachs R, Rübenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012;108:65-73.
27. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e326S-50.
28. Passaglia LG, de Barros GM, de Sousa MR. Early postoperative bridging anticoagulation after mechanical heart valve replacement: a systematic review and meta-analysis. J Thromb Haemost 2015;13:1557-67.
29. Ionescu A, Payne N, Fraser AG, et al. Incidence of embolism and paravalvar leak after St Jude Silzone valve implantation: experience from the Cardiff Embolic Risk Factor Study. Heart 2003;89:1055-61.
30. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulant on thrombi and morbidity after replacement of the mitral valve with the St. Jude medical prosthesis: a clinical and transesophageal echocardiographic study. J Am Coll Cardiol 2000;35:739-46.
31. Mathew JG, Spyropoulos AC, Yusuf A, et al. Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. Thromb Haemost 2014;112:1120-8.
32. Douketis JD, Syed S, Schulman S. Periprocedural management of direct oral anticoagulants: comment on the 2015 American society of regional anesthesia and pain medicine guidelines. Reg Anesth Pain Med 2016;41:127-9.
33. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American society of regional anesthesia and pain medicine, the European society of regional anaesthesia and pain therapy, the American academy of pain medicine, the international neuromodulation society, the North American neuromodulation society, and the world institute of pain. Reg Anesth Pain Med 2015;40:182-212.
34. Perioperative Anticoagulant Use for Surgery Evaluation Study (PAUSE). 12:20-16. https:// clinicaltrials. gov/ ct2/ show/ NCT02228798? term= pause&rank=1
35. Schulman S, Carrier M, Lee AY, et al.Perioperative management of dabigatran: a prospective cohort study. Circulation 2015;132:167-73.
36. Douketis JD, Wang G, Chan N, et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost 2016;14:89-97.
37. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 2016.
38. Ageno W, Büller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper. Thromb Haemost 2016;116:1003-10.
39. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:623-7.
40. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol 2011;27:208-21.
41. Myles PS, Smith JA, Forbes A, et al.Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 2016;374:728-37.
42. Holcomb CN, Graham LA, Richman JS, et al. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. J Am Coll Cardiol 2014;64:2730-9.
43. Egholm G, Kristensen SD, Thim T, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 2016;68:2622-32.
44. Fleisher LA, Fleischmann KE, Auerbach AD, et al.ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2014;64:e77-137.
45. Kristensen SD, Knuuti J, Saraste A, et al.2014 ESC/ ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014;31:517-73.
46. Fleisher LA, Fleischmann KE, Auerbach AD, et al. ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e27 8-e333.
47. Darvish-Kazem S, Gandhi M, Marcucci M, et al. Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines. Chest 2013;144:1848-1856.
48. Gherli R, Mariscalco G, Dalén M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016;1:921-8.
49. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265-74.
50. O'Connor SA, Amour J, Mercadier A, et al. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. Circ Cardiovasc Interv 2015;8:e002786.